183 related articles for article (PubMed ID: 23686402)
1. Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review.
Poi MJ; Berger M; Lustberg M; Layman R; Shapiro CL; Ramaswamy B; Mrozek E; Olson E; Wesolowski R
Support Care Cancer; 2013 Oct; 21(10):2679-86. PubMed ID: 23686402
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer.
Schwartz J; Domchek SM; Hwang WT; Fox K
Ann Oncol; 2005 Feb; 16(2):247-52. PubMed ID: 15668278
[TBL] [Abstract][Full Text] [Related]
3. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
[TBL] [Abstract][Full Text] [Related]
4. Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer.
Paciucci PA; Raptis G; Bleiweiss I; Weltz C; Lehrer D; Gurry R
Anticancer Drugs; 2002 Sep; 13(8):791-5. PubMed ID: 12394262
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of dose-dense doxorubicin and docetaxel as neoadjunvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer.
García-Mata J; García-Palomo A; Calvo L; Mel R; Cruz JJ; Ramos M
Clin Transl Oncol; 2008 Nov; 10(11):739-44. PubMed ID: 19015070
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
[TBL] [Abstract][Full Text] [Related]
7. Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).
Saloustros E; Malamos N; Boukovinas I; Kakolyris S; Kouroussis C; Athanasiadis A; Ziras N; Kentepozidis N; Makrantonakis P; Polyzos A; Christophyllakis C; Georgoulias V; Mavroudis D
Breast Cancer Res Treat; 2014 Dec; 148(3):591-7. PubMed ID: 25399229
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.
Ferraresi V; Milella M; Vaccaro A; D'Ottavio AM; Papaldo P; Nisticò C; Thorel MF; Marsella A; Carpino A; Giannarelli D; Terzoli E; Cognetti F
Am J Clin Oncol; 2000 Apr; 23(2):132-9. PubMed ID: 10776972
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies.
Wesolowski R; Peereboom D; Weiss P; Elson P; Thomas Budd G
Invest New Drugs; 2010 Aug; 28(4):502-8. PubMed ID: 19434371
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer.
Ibrahim NK; Rahman Z; Valero V; Murray JL; Frye D; Hortobagyi GN
Cancer Invest; 2002; 20(1):29-37. PubMed ID: 11852999
[TBL] [Abstract][Full Text] [Related]
11. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor.
Kwasny W; Kornek G; Haider K; Valencak J; Ulrich-Pur H; Penz M; Lang F; Depisch D; Scheithauer W
Breast Cancer Res Treat; 2000 Oct; 63(3):235-41. PubMed ID: 11110057
[TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor.
Kornek GV; Ulrich-Pur H; Penz M; Haider K; Kwasny W; Depisch D; Kovats E; Lang F; Schneeweiss B; Scheithauer W
J Clin Oncol; 2001 Feb; 19(3):621-7. PubMed ID: 11157011
[TBL] [Abstract][Full Text] [Related]
14. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
Liu MC; Demetri GD; Berry DA; Norton L; Broadwater G; Robert NJ; Duggan D; Hayes DF; Henderson IC; Lyss A; Hopkins J; Kaufman PA; Marcom PK; Younger J; Lin N; Tkaczuk K; Winer EP; Hudis CA;
Cancer Treat Rev; 2008 May; 34(3):223-30. PubMed ID: 18234424
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
16. [Neutropenia induced by taxoids and its control with granulocyte colony-stimulating factor].
Luis-Fernández J; Rangel-Mayoral JF; Estepa-Alonso MJ; Liso-Rubio FJ
Invest Clin; 2005 Sep; 46(3):265-72. PubMed ID: 16152782
[TBL] [Abstract][Full Text] [Related]
17. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
Dranitsaris G; Coleman R; Gradishar W
Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
[TBL] [Abstract][Full Text] [Related]
18. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study.
von Minckwitz G; Costa SD; Raab G; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Gademann G; Tulusan AH; Eiermann W; Graf E; Kaufmann M;
J Clin Oncol; 2001 Aug; 19(15):3506-15. PubMed ID: 11481357
[TBL] [Abstract][Full Text] [Related]
19. Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases.
Kim WY; Woo SU; Seo JH; Son GS; Lee JB; Bae JW
J Cancer Res Ther; 2011; 7(4):412-5. PubMed ID: 22269401
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer.
Mitchell PL; Basser R; Chipman M; Grigg A; Mansfield R; Cebon J; Davis ID; Appia F; Green M
Ann Oncol; 2004 Apr; 15(4):585-9. PubMed ID: 15033663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]